Array Biopharma Inc (ARRY) 4.22 $ARRY
Array BioPharma Announces Appointment Of Jason Haddock As Chief Financial Officer
PR Newswire - Thu Jul 28, 7:00AM CDT
Array BioPharma (NASDAQ: ARRY) ("Array"
, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, announced it has appointed Jason Haddock as Chief Financial Officer (CFO). Mr. Haddock's appointment was effective today and he will be replacing David Horin, who had been acting as Array's interim CFO. We wish to thank Mr. Horin for his service and commitment to Array. He will continue to provide services to Array on a consulting basis.
ARRY: 4.22 (+0.48)
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2016 On August 4, 2016
PR Newswire - Wed Jul 27, 3:56PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2016 and hold a conference call to discuss those results on Thursday, August 4, 2016. Ron Squarer, Chief Executive Officer, will lead the call.
ARRY: 4.22 (+0.48)
Array Presents Full Results from Phase 3 NEMO Study
PR Newswire - Mon Jun 06, 1:15PM CDT
Array BioPharma (Nasdaq: ARRY) announced full results at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract No. 9500) from the pivotal Phase 3 NEMO (NRAS MELANOMA AND MEK INHBITOR) trial of binimetinib. The study found binimetinib significantly extended median progression-free survival (PFS), the study's primary endpoint, at 2.8 months, as compared with 1.5 months observed with dacarbazine [hazard ratio (HR)=0.62 (95% CI 0.47-0.80), p<0.001] - the first trial to ever meet a PFS endpoint in patients with advanced NRAS-mutant melanoma. In the pre-specified subset of patients who received prior treatment with immunotherapy, including ipilimumab, nivolumab or pembrolizumab, patients who received binimetinib experienced 5.5 months of median PFS (95% CI, 2.8-7.6), compared with 1.6 months for those receiving treatment with dacarbazine (95% CI, 1.5-2.
.
ARRY: 4.22 (+0.48)
Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks
PR Newswire - Sat Jun 04, 8:00AM CDT
Array BioPharma (Nasdaq: ARRY) announced today updated results from a Phase 2 study of the combination of encorafenib and cetuximab, with or without alpelisib, in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). BRAFm CRC represents a difficult-to-treat subtype of colorectal cancer that impacts 8 to 15 percent of patients. Data from this study suggest that median overall survival (OS) for these patients may exceed one year which is more than double historical published benchmarks for this population. These data were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract No. 3544).
ARRY: 4.22 (+0.48)
Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial
PR Newswire - Sat Jun 04, 8:00AM CDT
Array BioPharma (Nasdaq: ARRY), Pierre Fabre and Merck KGaA, Darmstadt, Germany, today jointly initiated the BEACON CRC (Binimetinib, Encorafenib And Cetuximab Combined to treat BRAF-mutant Colorectal Cancer) trial, a randomized, global Phase 3 clinical trial designed to assess the safety and efficacy of binimetinib (MEK inhibitor), encorafenib (BRAF inhibitor) and Erbitux (monoclonal antibody) in comparison to Erbitux and irinotecan-based therapy in patients with BRAF-mutant colorectal cancer (BRAFm CRC). The primary endpoint is overall survival (OS) and key secondary endpoints include progression-free survival (PFS) and objective response rate (ORR).
ARRY: 4.22 (+0.48)
Array BioPharma To Present At The Jefferies 2016 Global Healthcare Conference
PR Newswire - Thu Jun 02, 1:20PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Jefferies 2016 Global Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
ARRY: 4.22 (+0.48)
Array BioPharma Announces Key Data from NRAS-mutant Melanoma and BRAF-mutant Colorectal Cancer ASCO 2016 Presentations
PR Newswire - Wed May 18, 4:05PM CDT
Array BioPharma (NASDAQ: ARRY) will present additional data on its late-stage candidates binimetinib and encorafenib in NRAS-mutant melanoma and BRAF-mutant colorectal cancer, respectively, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 3-7.
ARRY: 4.22 (+0.48)
Array BioPharma To Present At The Bank of America Merrill Lynch HealthCare Conference
PR Newswire - Thu May 05, 6:00PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas. The public is welcome to participate in the conferences through a webcast on the Array BioPharma website.
ARRY: 4.22 (+0.48)
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2016
PR Newswire - Tue May 03, 7:00AM CDT
Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies, today reported results for its fiscal year third quarter ending March 31, 2016 and provided an update on the progress of its key clinical development programs.
ARRY: 4.22 (+0.48)
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2016 On May 3, 2016
PR Newswire - Tue Apr 26, 11:25AM CDT
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2016 and hold a conference call to discuss those results on Tuesday, May 3, 2016. Ron Squarer, Chief Executive Officer, will lead the call.
ARRY: 4.22 (+0.48)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 6.07 (+0.18), EBIO: 3.80 (-0.17), PTCT: 6.10 (+0.13), PETX: 7.50 (-0.09), ARRY: 4.22 (+0.48)
Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer
PR Newswire - Fri Apr 01, 8:00AM CDT
Array BioPharma Inc. (Nasdaq: ARRY) announced today its decision to discontinue the MILO study, a Phase 3 trial of binimetinib for the treatment of patients with low-grade serous ovarian cancer. The decision to stop the study was made after a planned interim analysis showed that the Hazard Ratio for Progression Free Survival (PFS) crossed the predefined futility boundary. Top-line results from the study had been expected in 2017.
ARRY: 4.22 (+0.48)
Array BioPharma And Asahi Kasei Pharma Corporation Announce Development And Commercialization Collaboration For Novel Pain And Inflammation Program
PR Newswire - Thu Mar 31, 8:00AM CDT
Array BioPharma Inc. (Nasdaq: ARRY) and Asahi Kasei Pharma Corporation today announced a strategic collaboration to develop and commercialize select Tropomyosin receptor kinase A (TrkA) inhibitors, including Array-invented ARRY-954, for pain, inflammation and other non-cancer indications. Array retains the right for all compounds for all indications outside of Asia. Within Asia, Array retains the right to cancer indications for all compounds, excluding those compounds being developed by Asahi Kasei Pharma, including ARRY-954.
ARRY: 4.22 (+0.48)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 8.47 (+0.13), ADRO: 14.84 (+0.16), ARWR: 5.86 (-0.10), ADMP: 2.77 (-0.04), AMGN: 174.16 (+2.13), APTO: 2.51 (-0.01), AVXL: 3.61 (-0.23), AZN: 33.84 (-0.30), ABBV: 66.94 (+0.71), ARRY: 4.22 (+0.48)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 33.84 (-0.30), ACH: 8.23 (+0.17), CYTR: 0.60 (-0.05), AVEO: 0.99 (-0.01), ARQL: 1.68 (+0.02), CTIC: 0.34 (unch), ARRY: 4.22 (+0.48)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 22.11 (unch), BSPM: 4.25 (-0.07), ADRO: 14.84 (+0.16), ARWR: 5.86 (-0.10), ARQL: 1.68 (+0.02), AMGN: 174.16 (+2.13), CASI: 1.10 (+0.01), BMY: 76.19 (+1.38), CLBS: 5.70 (+0.16), AAAP: 31.59 (+0.30), CANF: 2.10 (unch), ABUS: 4.17 (+0.08), AZN: 33.84 (-0.30), AVEO: 0.99 (-0.01), ABBV: 66.94 (+0.71), XLRN: 34.40 (+0.48), ARRY: 4.22 (+0.48)
Type 2 Diabetes Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/82p26k/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetesand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type 2 DiabetesOverview - Therapeutics Development - Pipeline Products for Type 2 Diabetes- Overview - Pipeline Products for Type 2 Diabetes- Comparative Analysis - Type 2 Diabetes- Therapeutics under Development by Companies - Type 2 Diabetes- Therapeutics under Investigation by Universities/Institutes - Type 2 Diabetes- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type 2 Diabetes- Products under Development by Companies - Type 2 Diabetes- Products under Investigation by Universities/Institutes - Type 2 Diabetes- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - Addex Therapeutics Ltd - Adocia - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - AFFiRiS AG - Alchemia Limited - Alize Pharma SAS - AlphaMab Co., Ltd - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - Amgen Inc. - Anchor Therapeutics, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Arisaph Pharmaceuticals, Inc. - ArisGen SA - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AUS Bio Limited - Avaxia Biologics, Inc. - Bayer AG - Beta-Cell NV - Betagenon AB - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLingus AG - BioRestorative Therapies, Inc. - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/82...2_diabetes
AMBX: (), AMGN: 174.16 (+2.13), BIOD: 0.41 (-0.03), AZN: 33.84 (-0.30), ARRY: 4.22 (+0.48)
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.47 (+0.13), ARQL: 1.68 (+0.02), AMGN: 174.16 (+2.13), ATNM: 1.71 (-0.07), AZN: 33.84 (-0.30), AVEO: 0.99 (-0.01), ABBV: 66.94 (+0.71), BXLT: 46.02 (-0.18), ARRY: 4.22 (+0.48)
Metastatic Colorectal Cancer Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/pdf2gt/metastatic) has announced the addition of the "Metastatic Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Metastatic Colorectal Cancer Overview - Therapeutics Development - Pipeline Products for Metastatic Colorectal Cancer - Overview - Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis - Metastatic Colorectal Cancer - Therapeutics under Development by Companies - Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Metastatic Colorectal Cancer - Products under Development by Companies - Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Amgen Inc. - Apexigen, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - Biocon Limited - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cornerstone Pharmaceuticals, Inc. - DanDrit Biotech A/S - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - Epirus Biopharmaceuticals, Inc. - Etubics Corporation - Exelixis, Inc. For more information visit http://www.researchandmarkets.com/research/pdf2gt/metastatic
ARQL: 1.68 (+0.02), AMGN: 174.16 (+2.13), LLY: 83.18 (+0.29), BMY: 76.19 (+1.38), ATNM: 1.71 (-0.07), AZN: 33.84 (-0.30), AVEO: 0.99 (-0.01), ABBV: 66.94 (+0.71), BXLT: 46.02 (-0.18), EXEL: 9.27 (+0.09), CELGZ: 1.14 (-0.02), ARRY: 4.22 (+0.48)
Multiple Sclerosis - Pipeline Review, H2 2015 Featuring 174 Companies
M2 - Fri Feb 05, 9:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/97qgw2/multiple) has announced the addition of the "Multiple Sclerosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Sclerosis Overview - Therapeutics Development - Pipeline Products for Multiple Sclerosis - Overview - Pipeline Products for Multiple Sclerosis - Comparative Analysis - Multiple Sclerosis - Therapeutics under Development by Companies - Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes - Multiple Sclerosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Sclerosis - Products under Development by Companies - Multiple Sclerosis - Products under Investigation by Universities/Institutes - Multiple Sclerosis - Companies Involved in Therapeutics Development - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Ablynx NV - Acorda Therapeutics, Inc. - Actelion Ltd - Addex Therapeutics Ltd - Aegera Therapeutics Inc. - Aegis Therapeutics, LLC - Affectis Pharmaceuticals AG - AiCuris GmbH & Co. KG - Alkermes Plc - Allozyne, Inc. - Amarna Therapeutics B.V. - Antipodean Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Antitope Limited - Aphios Corporation - Apitope International NV - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artielle ImmunoTherapeutics, Inc. - Athersys, Inc. - Axxam SpA - Baliopharm AG - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited - Biogen, Inc. - Biogenomics Limited - Biokine Therapeutics Ltd. - Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/97qgw2/multiple About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ACOR: 25.13 (-0.15), ALKS: 49.56 (-0.34), ARGS: 5.31 (+0.05), ABBV: 66.94 (+0.71), ATHX: 2.17 (-0.05), ARNA: 1.68 (+0.01), ARRY: 4.22 (+0.48)
Array BioPharma Announces Appointment Of Jason Haddock As Chief Financial Officer
PR Newswire - Thu Jul 28, 7:00AM CDT
Array BioPharma (NASDAQ: ARRY) ("Array"
, a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, announced it has appointed Jason Haddock as Chief Financial Officer (CFO). Mr. Haddock's appointment was effective today and he will be replacing David Horin, who had been acting as Array's interim CFO. We wish to thank Mr. Horin for his service and commitment to Array. He will continue to provide services to Array on a consulting basis. ARRY: 4.22 (+0.48)
Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2016 On August 4, 2016
PR Newswire - Wed Jul 27, 3:56PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2016 and hold a conference call to discuss those results on Thursday, August 4, 2016. Ron Squarer, Chief Executive Officer, will lead the call.
ARRY: 4.22 (+0.48)
Array Presents Full Results from Phase 3 NEMO Study
PR Newswire - Mon Jun 06, 1:15PM CDT
Array BioPharma (Nasdaq: ARRY) announced full results at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract No. 9500) from the pivotal Phase 3 NEMO (NRAS MELANOMA AND MEK INHBITOR) trial of binimetinib. The study found binimetinib significantly extended median progression-free survival (PFS), the study's primary endpoint, at 2.8 months, as compared with 1.5 months observed with dacarbazine [hazard ratio (HR)=0.62 (95% CI 0.47-0.80), p<0.001] - the first trial to ever meet a PFS endpoint in patients with advanced NRAS-mutant melanoma. In the pre-specified subset of patients who received prior treatment with immunotherapy, including ipilimumab, nivolumab or pembrolizumab, patients who received binimetinib experienced 5.5 months of median PFS (95% CI, 2.8-7.6), compared with 1.6 months for those receiving treatment with dacarbazine (95% CI, 1.5-2.
. ARRY: 4.22 (+0.48)
Encorafenib-based Regimens Provide Improved PFS and OS in Difficult-to-Treat BRAF-Mutant Colorectal Cancer Compared to Historical Benchmarks
PR Newswire - Sat Jun 04, 8:00AM CDT
Array BioPharma (Nasdaq: ARRY) announced today updated results from a Phase 2 study of the combination of encorafenib and cetuximab, with or without alpelisib, in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). BRAFm CRC represents a difficult-to-treat subtype of colorectal cancer that impacts 8 to 15 percent of patients. Data from this study suggest that median overall survival (OS) for these patients may exceed one year which is more than double historical published benchmarks for this population. These data were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract No. 3544).
ARRY: 4.22 (+0.48)
Array BioPharma, Pierre Fabre and Merck KGaA, Darmstadt, Germany Announce Phase 3 BEACON CRC Trial
PR Newswire - Sat Jun 04, 8:00AM CDT
Array BioPharma (Nasdaq: ARRY), Pierre Fabre and Merck KGaA, Darmstadt, Germany, today jointly initiated the BEACON CRC (Binimetinib, Encorafenib And Cetuximab Combined to treat BRAF-mutant Colorectal Cancer) trial, a randomized, global Phase 3 clinical trial designed to assess the safety and efficacy of binimetinib (MEK inhibitor), encorafenib (BRAF inhibitor) and Erbitux (monoclonal antibody) in comparison to Erbitux and irinotecan-based therapy in patients with BRAF-mutant colorectal cancer (BRAFm CRC). The primary endpoint is overall survival (OS) and key secondary endpoints include progression-free survival (PFS) and objective response rate (ORR).
ARRY: 4.22 (+0.48)
Array BioPharma To Present At The Jefferies 2016 Global Healthcare Conference
PR Newswire - Thu Jun 02, 1:20PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Jefferies 2016 Global Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
ARRY: 4.22 (+0.48)
Array BioPharma Announces Key Data from NRAS-mutant Melanoma and BRAF-mutant Colorectal Cancer ASCO 2016 Presentations
PR Newswire - Wed May 18, 4:05PM CDT
Array BioPharma (NASDAQ: ARRY) will present additional data on its late-stage candidates binimetinib and encorafenib in NRAS-mutant melanoma and BRAF-mutant colorectal cancer, respectively, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 3-7.
ARRY: 4.22 (+0.48)
Array BioPharma To Present At The Bank of America Merrill Lynch HealthCare Conference
PR Newswire - Thu May 05, 6:00PM CDT
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Bank of America Merrill Lynch Healthcare Conference in Las Vegas. The public is welcome to participate in the conferences through a webcast on the Array BioPharma website.
ARRY: 4.22 (+0.48)
Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2016
PR Newswire - Tue May 03, 7:00AM CDT
Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule cancer therapies, today reported results for its fiscal year third quarter ending March 31, 2016 and provided an update on the progress of its key clinical development programs.
ARRY: 4.22 (+0.48)
Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2016 On May 3, 2016
PR Newswire - Tue Apr 26, 11:25AM CDT
Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2016 and hold a conference call to discuss those results on Tuesday, May 3, 2016. Ron Squarer, Chief Executive Officer, will lead the call.
ARRY: 4.22 (+0.48)
Why Patents are the Lifeblood of Biotech Companies
ACCESSWIRE - Mon Apr 25, 8:36AM CDT
Protection of Intellectual Property Is At the Core of the Business for Biotechnology Firms
RPTP: 6.07 (+0.18), EBIO: 3.80 (-0.17), PTCT: 6.10 (+0.13), PETX: 7.50 (-0.09), ARRY: 4.22 (+0.48)
Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer
PR Newswire - Fri Apr 01, 8:00AM CDT
Array BioPharma Inc. (Nasdaq: ARRY) announced today its decision to discontinue the MILO study, a Phase 3 trial of binimetinib for the treatment of patients with low-grade serous ovarian cancer. The decision to stop the study was made after a planned interim analysis showed that the Hazard Ratio for Progression Free Survival (PFS) crossed the predefined futility boundary. Top-line results from the study had been expected in 2017.
ARRY: 4.22 (+0.48)
Array BioPharma And Asahi Kasei Pharma Corporation Announce Development And Commercialization Collaboration For Novel Pain And Inflammation Program
PR Newswire - Thu Mar 31, 8:00AM CDT
Array BioPharma Inc. (Nasdaq: ARRY) and Asahi Kasei Pharma Corporation today announced a strategic collaboration to develop and commercialize select Tropomyosin receptor kinase A (TrkA) inhibitors, including Array-invented ARRY-954, for pain, inflammation and other non-cancer indications. Array retains the right for all compounds for all indications outside of Asia. Within Asia, Array retains the right to cancer indications for all compounds, excluding those compounds being developed by Asahi Kasei Pharma, including ARRY-954.
ARRY: 4.22 (+0.48)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 8.47 (+0.13), ADRO: 14.84 (+0.16), ARWR: 5.86 (-0.10), ADMP: 2.77 (-0.04), AMGN: 174.16 (+2.13), APTO: 2.51 (-0.01), AVXL: 3.61 (-0.23), AZN: 33.84 (-0.30), ABBV: 66.94 (+0.71), ARRY: 4.22 (+0.48)
Non-Small Cell Lung Cancer - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnx7gl/nonsmall_cell) has announced the addition of the "Non-Small Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Non-Small Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Non-Small Cell Lung Cancer - Overview - Pipeline Products for Non-Small Cell Lung Cancer - Comparative Analysis - Non-Small Cell Lung Cancer - Therapeutics under Development by Companies - Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Non-Small Cell Lung Cancer - Products under Development by Companies - Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes - Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development Companies Mentioned: - Arch Biopartners, Inc. - Ariad Pharmaceuticals, Inc. - Arog Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Axelar AB - CTI BioPharma Corp. - CureFAKtor Pharmaceuticals, LLC - CureVac GmbH - CytRx Corporation - Daiichi Sankyo Company, Limited - DanDrit Biotech A/S - Viralytics Ltd. - XBiotech USA, Inc. - Zhejiang BetaPharma Co., Ltd. - Zyngenia, Inc. - (200 Others) For more information visit http://www.researchandmarkets.com/research/pn...small_cell
AZN: 33.84 (-0.30), ACH: 8.23 (+0.17), CYTR: 0.60 (-0.05), AVEO: 0.99 (-0.01), ARQL: 1.68 (+0.02), CTIC: 0.34 (unch), ARRY: 4.22 (+0.48)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 22.11 (unch), BSPM: 4.25 (-0.07), ADRO: 14.84 (+0.16), ARWR: 5.86 (-0.10), ARQL: 1.68 (+0.02), AMGN: 174.16 (+2.13), CASI: 1.10 (+0.01), BMY: 76.19 (+1.38), CLBS: 5.70 (+0.16), AAAP: 31.59 (+0.30), CANF: 2.10 (unch), ABUS: 4.17 (+0.08), AZN: 33.84 (-0.30), AVEO: 0.99 (-0.01), ABBV: 66.94 (+0.71), XLRN: 34.40 (+0.48), ARRY: 4.22 (+0.48)
Type 2 Diabetes Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/82p26k/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetesand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type 2 DiabetesOverview - Therapeutics Development - Pipeline Products for Type 2 Diabetes- Overview - Pipeline Products for Type 2 Diabetes- Comparative Analysis - Type 2 Diabetes- Therapeutics under Development by Companies - Type 2 Diabetes- Therapeutics under Investigation by Universities/Institutes - Type 2 Diabetes- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type 2 Diabetes- Products under Development by Companies - Type 2 Diabetes- Products under Investigation by Universities/Institutes - Type 2 Diabetes- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 3SBio Inc. - Addex Therapeutics Ltd - Adocia - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - AFFiRiS AG - Alchemia Limited - Alize Pharma SAS - AlphaMab Co., Ltd - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - Amgen Inc. - Anchor Therapeutics, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Arisaph Pharmaceuticals, Inc. - ArisGen SA - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AUS Bio Limited - Avaxia Biologics, Inc. - Bayer AG - Beta-Cell NV - Betagenon AB - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLingus AG - BioRestorative Therapies, Inc. - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/82...2_diabetes
AMBX: (), AMGN: 174.16 (+2.13), BIOD: 0.41 (-0.03), AZN: 33.84 (-0.30), ARRY: 4.22 (+0.48)
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.47 (+0.13), ARQL: 1.68 (+0.02), AMGN: 174.16 (+2.13), ATNM: 1.71 (-0.07), AZN: 33.84 (-0.30), AVEO: 0.99 (-0.01), ABBV: 66.94 (+0.71), BXLT: 46.02 (-0.18), ARRY: 4.22 (+0.48)
Metastatic Colorectal Cancer Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/pdf2gt/metastatic) has announced the addition of the "Metastatic Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Metastatic Colorectal Cancer Overview - Therapeutics Development - Pipeline Products for Metastatic Colorectal Cancer - Overview - Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis - Metastatic Colorectal Cancer - Therapeutics under Development by Companies - Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Metastatic Colorectal Cancer - Products under Development by Companies - Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Amgen Inc. - Apexigen, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - Biocon Limited - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cornerstone Pharmaceuticals, Inc. - DanDrit Biotech A/S - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - Epirus Biopharmaceuticals, Inc. - Etubics Corporation - Exelixis, Inc. For more information visit http://www.researchandmarkets.com/research/pdf2gt/metastatic
ARQL: 1.68 (+0.02), AMGN: 174.16 (+2.13), LLY: 83.18 (+0.29), BMY: 76.19 (+1.38), ATNM: 1.71 (-0.07), AZN: 33.84 (-0.30), AVEO: 0.99 (-0.01), ABBV: 66.94 (+0.71), BXLT: 46.02 (-0.18), EXEL: 9.27 (+0.09), CELGZ: 1.14 (-0.02), ARRY: 4.22 (+0.48)
Multiple Sclerosis - Pipeline Review, H2 2015 Featuring 174 Companies
M2 - Fri Feb 05, 9:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/97qgw2/multiple) has announced the addition of the "Multiple Sclerosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Sclerosis Overview - Therapeutics Development - Pipeline Products for Multiple Sclerosis - Overview - Pipeline Products for Multiple Sclerosis - Comparative Analysis - Multiple Sclerosis - Therapeutics under Development by Companies - Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes - Multiple Sclerosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Sclerosis - Products under Development by Companies - Multiple Sclerosis - Products under Investigation by Universities/Institutes - Multiple Sclerosis - Companies Involved in Therapeutics Development - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Ablynx NV - Acorda Therapeutics, Inc. - Actelion Ltd - Addex Therapeutics Ltd - Aegera Therapeutics Inc. - Aegis Therapeutics, LLC - Affectis Pharmaceuticals AG - AiCuris GmbH & Co. KG - Alkermes Plc - Allozyne, Inc. - Amarna Therapeutics B.V. - Antipodean Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Antitope Limited - Aphios Corporation - Apitope International NV - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artielle ImmunoTherapeutics, Inc. - Athersys, Inc. - Axxam SpA - Baliopharm AG - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited - Biogen, Inc. - Biogenomics Limited - Biokine Therapeutics Ltd. - Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/97qgw2/multiple About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ACOR: 25.13 (-0.15), ALKS: 49.56 (-0.34), ARGS: 5.31 (+0.05), ABBV: 66.94 (+0.71), ATHX: 2.17 (-0.05), ARNA: 1.68 (+0.01), ARRY: 4.22 (+0.48)
